Aerie Pharmaceuticals Inc. (AERI) Stock
AERI is no longer traded. Aerie Pharmaceuticals was delisted from the Nasdaq in November 2022.
Prices on this page are historical; the last trade was November 18, 2022 at $15.25.
Aerie Pharmaceuticals stock price history
AERI final trading statistics
- Final close
- $15.25
- Final trading day
- Nov 18, 2022
- Market cap at delisting
- $753.62M
- Shares outstanding
- 49.42M
- Final 52-week range
- $4.81 – $15.37
- Avg. volume (final 3 mo.)
- 1,625,604
- All-time high (split-adj.)
- $73.90 · Jul 2018
- All-time low (split-adj.)
- $4.95 · Jun 2022
- Return since IPO
- +43.7%
- Beta
- -0.06
- Book value / share
- -$3.32
- Price / book
- -4.59
Aerie Pharmaceuticals annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $194.13M | -$74.8M | -$1.02 |
| FY2020 | $83.14M | -$183.1M | -$3.10 |
| FY2019 | $69.89M | -$199.6M | -$3.40 |
| FY2018 | $24.18M | -$232.6M | -$4.62 |
| FY2017 | $0.00 | -$145.1M | -$3.34 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Aerie Pharmaceuticals Inc.
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.
Aerie Pharmaceuticals stock FAQ
What happened to Aerie Pharmaceuticals stock?
Aerie Pharmaceuticals stock was delisted from the Nasdaq. Its final close was $15.25 on November 18, 2022.
Is AERI stock still trading?
No. AERI was delisted from the Nasdaq in November 2022 and no longer trades on a U.S. exchange.
What was the last price of AERI stock?
AERI closed at $15.25 on its final trading day, November 18, 2022, for a market value of about $753.62M.
What were Aerie Pharmaceuticals's revenue and earnings in its last full fiscal year?
Aerie Pharmaceuticals reported revenue of $194.13M and net income of -$74.8M in fiscal 2021, its last full year as a public company.
When did Aerie Pharmaceuticals go public?
Aerie Pharmaceuticals Inc. stock began trading on October 25, 2013.